Formycon AG announced that effective July 1, 2022, the Supervisory Board of Formycon AG appointed Dr. Stefan Glombitza, who has led Formycon's operational development activities as Chief Operating Officer (COO) since 2016, as Chief Executive Officer (CEO). Dr. Glombitza thus takes over the position from Dr. Carsten Brockmeyer, who leaves the Executive Board as planned on June 30, 2022, when his appointment regularly expires. Dr. Brockmeyer will continue to support the company as a scientific advisor.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
55.2 EUR | -1.08% | +15.55% | -2.48% |
18/06 | Borse Frankfurt-News: Many winners and many losers (second-line stocks) | DP |
13/06 | Formycon Starts Clinical Trials of Keytruda Biosimilar Candidate for Skin Cancer Therapy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.48% | 1.05B | |
+38.36% | 52.73B | |
+38.82% | 39B | |
-8.63% | 38.52B | |
+25.46% | 30.38B | |
-11.17% | 26.39B | |
+11.44% | 26.08B | |
+45.09% | 14.15B | |
+32.93% | 12.6B | |
-5.30% | 11.51B |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- Formycon AG Announces CEO Changes